In the long journey of cancer treatment technology development, we have been pursuing a “magic bullet” that can accurately identify and eliminate cancer cells while sparing normal cells.ADC drugs—Antibody-Drug Conjugates—are a new therapeutic approach that comes close to this ideal. In recent years,ADC drugs have achieved remarkable success in the field of tumor treatment, with … Read more
When the dual-antibody ADC drug iza-bren presented an astonishing “objective response rate of 100%” at the 2025 World Lung Cancer Conference, this category of drugs, known as “biological missiles,” completely rewrote the narrative logic of tumor treatment. From the first approved drug, trastuzumab, to the domestically developed dual-antibody ADCs, ADC drugs have established a foothold … Read more
Xiao-Jun Zhao Associate Professor Department of Urology, First Affiliated Hospital of Soochow University, Chief Physician, Doctor of Medicine, Master’s Supervisor. Young Committee Member of the Urology Society of Suzhou Medical Association,Executive Committee Member of the Suzhou Society of Integrated Traditional Chinese and Western Medicine in Urology,Member of the Minimally Invasive Treatment Professional Committee of the … Read more
The field of ovarian cancer treatment is evolving at an unprecedented pace. With continuous advancements in surgical techniques and the emergence of new therapies, patients’ survival prospects are steadily improving. However, as Dr. Ryan M. Kahn, a gynecologic oncologist at Baptist Health Miami Cancer Institute, states, we still need to address ongoing challenges and unmet … Read more
（Image and text author: Li Dan）
What else can DS-8201 not do? Recently, the “miraculous anti-cancer drug” DS-8201 announced data from its DESTINY-Breast03 trial involving patients with brain metastases[1]: Among 43 patients with HER2-positive breast cancer brain metastases treated with DS-8201, the median progression-free survival reached 15.0 months, with intracranial objective response rate and overall objective response rate at 65.7% and … Read more